Shots: The first P-III AReSVi 004 study evaluates the immunogenicity, safety, reactogenicity and persistence of RSV candidate vaccine in 1650 adults ≥ aged 60 years. The study is expected to […]readmore
Tags : Programme
Shots: The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9,000+ patients with anemia + CKD not on dialysis (NDD) , dialysis-dependent (DD), ID respectively […]readmore